Platelets as Alarkers of Hypercoagulability. In the laboratory there are a variety of methods to assess platelet function. These include the bleeding time, turnover studies of labeled platelets, adhesiveness of platelets to glass and other foreign surfaces, platelet factor III assays, release of serotonin and platelet factor IV, platelet adenylcyclase and cyclic-AMP levels, and platelet aggregation induced by various agents. In fact, once the role of platelet aggregation in initiating white-thrombus formation was fully appreciated, there was a clear desire to study this phenomenon. The manufacture of a simple aggregometer, which permits turbidometric measurement of platelet concentration, wherein optical density varies with platelet aggregation, has markedly facilitated such studies, and many compounds have been recognized as inhibitors of platelet aggregation. 7 Which agents known to modify platelet behavior are likely to be antithrombotic in arteries? Which assay or assays of platelet function should be used to monitor such antithrombotic activity? The answers to these questions are not presently available. In vitro, platelets can adhere to each other and to foreign surfaces. Thrombocytes can also release or take up various substances, initiate clot retraction, and change their shape as well 53 In the latter trial, overall mortality was significantly lower in the streptokinasetreated group than the heparin-treated group (18.5 vs 26.3%; 0.027 P> 0.01), although in contrast to the German study49 there was not a significant difference in the mortality with n the first 24 hours. The streptokinase group had more complications, chiefly bleeding and temperature elevations. The conclusion was that streptokinase effected a definite reduction in mortality, but that recommendations for its use would require further study, particularly in well-controlled coronary care units.
It is clear from the literature that there is a real and urgent need for a single, large, multicentered, controlled clinical trial to resolve once and for all the question of whether mortality in acute myocardial infarction can be favorably influenced by thrombolytic therapy. Before a definitive trial can be instituted, further data on the optimum dose and duration of urokinase therapy need to be obtained. Some of this information may hopefully be derived from the ongoing National Institutes of Health trial of urokinase in pulmonary embolism.
The rigorous and unending demands of an acceptable clinical trial in acute myocardial infarction are now well appreciated. This is also true of the capacity to define the patient population to be studied, which has been greatly facilitated by the existence of coronary care units and improved sophistication in monitoring the various clinical and laboratory parameters of myocardial infarction. If the trial population is adequate in size, and carefully supervised over a long enough period of time, it will be possible to recognize whether or not there are benefits to the overall treated population or whether there may be, in fact, benefits restricted to one or more subdivisions of the trial population. Difficult as it may be to demonstrate a decrease in mortality, an even greater problem will be the gathering of data to support the suggestion of several investigators48,34 that the size of the myocardial infarct may be reduced by thrombolytic therapy. There is real doubt as to whether adequate hemodynamic or pathologic data can be derived from a clinical trial to answer this question.
